Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat domain 13 (*WDR13*) encodes a member of the WD repeat protein family, which is characterized by multiple WD repeat motifs, each approximately 40 amino acids long often ending with a tryptophan-aspartic acid pair[3][1][4]. WDR repeat proteins, including WDR13, adopt a beta propeller fold and serve as stable platforms for the assembly of multiprotein complexes, facilitating processes such as cell cycle progression, signal transduction, apoptosis, and gene regulation without intrinsic catalytic activity[1][4]. WDR13 is thought to negatively regulate pancreatic beta cell proliferation (based on mouse studies), with gene knockout resulting in increased pancreatic islet mass and higher serum insulin and mild obesity[3]. WD repeat domain proteins are involved in numerous cellular processes but are not typically considered direct drug targets due to the lack of enzymatic activity or classical ligand binding[4].
Not applicable; no drugs are known to specifically target WDR13. The protein acts primarily as a scaffold in multiprotein complexes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat domain 13 (WDR13).